#103: TheMachine: AMGN Stock News : Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
'Coping with Cancer from the Outside In' Program to... |
May 25, 2009
11:31:08 PM |
#102: Stock News Bot: AMGN Stock: Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast Cancer
THOUSAND OAKS, Calif., Dec. 19
/PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN... |
December 24, 2008
09:32:01 AM |
#101: TheMachine: Amgen Receives Executive Summary from Independent Cochrane Collaboration Review of ESAs in Oncology
Amgen Inc., (NASDAQ: AMGN) announced it has received a summary of
... |
September 30, 2008
09:37:05 PM |
#100: Stock News Bot: Amgen Announces Voting Results of Annual Meeting of Stockholders
Amgen (NASDAQ:AMGN), today announced results of voting at the company’s
... |
May 9, 2008
06:21:24 PM |
#99: TheMachine: Amgen's Oncology Pipeline Data Highlighted at Upcoming Scientific Meeting
Five Investigational Compounds from Robust Ongoing Clinical Trials
... |
April 8, 2008
02:30:13 AM |
#97: FastFun: Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized Patients Met Primary Endpoints and Out of the Gate: Celgene Falls
--(www.USEquityNews.com)-- 12/11/2007 - Pharmaceutical industry alert... |
December 12, 2007
10:15:51 PM |
#96: FastFun: Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized Patients Met Primary Endpoints
Data Also Shows Potential of Nplate as a Long-term Treatment Option for... |
December 10, 2007
10:05:55 PM |
#95: FastFun: Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints
Data Show Romiplostim Increased and Sustained Platelet Counts in... |
December 10, 2007
10:05:13 PM |
#94: FastFun: Amgen in Discussions with FDA to Update U.S. Prescribing Information for ESAs
Revised ESA Labeling to be Based on New Data from PREPARE and GOG... |
December 7, 2007
08:25:04 PM |
#93: FastFun: Vectibix(R) Approved in the European Union for the Treatment of Metastatic Colorectal Cancer
Clinically Relevant Biomarker Provides Physicians With the Ability to... |
December 7, 2007
08:24:06 PM |
#92: FastFun: Amgen Announces Interim Results of Aranesp(R) ''PREPARE'' Study in Breast Cancer Patients
Amgen, Inc. (NASDAQ: AMGN) today announced that it had received interim... |
December 7, 2007
08:16:56 PM |
#91: FastFun: Amgen Hires Former Clinton Aide to Lobby and Gilead Seeks Aztreonam Lysine Approval
--(www.USEquityNews.com)-- 11/19/2007 - Pharmaceutical industry alert... |
November 26, 2007
08:31:13 PM |
#90: FastFun: Gilead Sciences CEO Exercises Options and Genzyme Rises After Icahn Buys Shares
--(www.USEquityNews.com)-- 11/16/2007 - Pharmaceutical industry alert... |
November 26, 2007
08:28:20 PM |
#89: Stock News Bot: AMGN News Amgen to Present at the Lehman Brothers Tenth Annual Global Healthcare Conference
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN) will participate in... |
March 19, 2007
09:43:00 AM |
#88: Stock News Bot: AMGN News Amgen to Present at the 27th Annual Cowen & Company Health Care Conference
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN) will participate in... |
March 12, 2007
11:53:00 AM |
